One-year Outcome of Everolimus With Standard-dose Tacrolimus Immunosuppression in De Novo ABO-incompatible Living Donor Kidney Transplantation: A Retrospective, Single-center, Propensity Score Matching Comparison With Mycophenolate in 42 Transplants

BACKGROUND. Despite improvement in immunosuppressive therapy, long-term kidney allograft survival remains a major challenge. The outcomes of therapy with everolimus (EVR) and standard-dose tacrolimus (Tac) have not been compared with those of mycophenolate mofetil (MMF) and standard-dose Tac in reci...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Hiroshi, Tsuchimoto, Akihiro, Ueki, Kenji, Kaku, Keizo, Okabe, Yasuhiro, Nakamura, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964930/
https://www.ncbi.nlm.nih.gov/pubmed/32047842
http://dx.doi.org/10.1097/TXD.0000000000000962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964930/
https://www.ncbi.nlm.nih.gov/pubmed/32047842
http://dx.doi.org/10.1097/TXD.0000000000000962

Ejemplares similares